ABT Stock Summary and Trading Ideas (Abbott Laboratories | NYSE:ABT)

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Abbott Laboratories trades on the NYSE stock market under the symbol ABT.

As of May 23, 2025, ABT stock price declined to $131.30 with 5,313,516 million shares trading.

ABT has a beta of 0.27, meaning it tends to be less sensitive to market movements. ABT has a correlation of 0.05 to the broad based SPY ETF.

ABT has a market cap of $227.73 billion. This is considered a Mega Cap stock.

Last quarter Abbott Laboratories reported $10 billion in Revenue and $1.09 earnings per share. This fell short of revenue expectation by $-32 million and exceeded earnings estimates by $.02.

In the last 3 years, ABT traded as high as $141.23 and as low as $89.67.

The top ETF exchange traded funds that ABT belongs to (by Net Assets): VTI, VOO, SPY, IVV, VTV.

ABT has outperformed the market in the last year with a return of +27.4%, while the SPY ETF gained +10.7%. In the last 3 month period, ABT beat the market returning -2.2%, while SPY returned -3.2%. However, in the most recent 2 weeks ABT has underperformed the stock market by returning -2.0%, while SPY returned +2.5%.

ABT support price is $129.61 and resistance is $133.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABT shares will trade within this expected range on the day.